Eli Lilly and : Q4 2022 Financial Workbook

Income Statement

LLY
Eli Lilly and Company
Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information *
Investor Relations
Joe Fletcher [phone]
Michael Sprengnether [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
Three Months Ended	Three Months Ended	Twelve Months Ended	Twelve Months Ended
($ in millions, except per share data)	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
GAAP Reported	% Chng	Adjust- ments †	Non-GAAP Adjusted	% Chng	GAAP Reported	Adjust- ments †	Non-GAAP Adjusted	GAAP Reported	% Chng	Adjust- ments †	Non-GAAP Adjusted	% Chng	GAAP Reported	Adjust- ments †	Non-GAAP Adjusted
Revenue	$ 7,301.8	(9)%	$ 7,301.8	(9)%	$ 7,999.9	$ 7,999.9	$ 28,541.4	1 %	$ 28,541.4	1 %	$ 28,318.4	$ 28,318.4
Cost of sales	1,548.1	(24)%	(124.1)	$ 1,424.0	(26)%	2,050.2	(137.4)	1,912.8	6,629.8	(9)%	(574.1)	$ 6,055.7	(5)%	7,312.8	(908.8)	6,404.0
Gross margin	5,753.7	(3)%	124.1	$ 5,877.8	(3)%	5,949.7	137.4	6,087.1	21,911.6	4 %	574.1	$ 22,485.7	3 %	21,005.6	908.8	21,914.4
% of total revenue	78.8%	4.4	pp	80.5%	4.4	pp	74.4%	76.1%	76.8%	2.6	pp	78.8%	1.4	pp	74.2%	77.4%
Research and development	1,995.9	5 %	$ 1,995.9	5 %	1,898.3	1,898.3	7,190.8	4 %	$ 7,190.8	4 %	6,930.7	6,930.7
Marketing, selling and administrative	1,643.2	3 %	$ 1,643.2	3 %	1,592.0	1,592.0	6,440.4	- %	$ 6,440.4	- %	6,431.6	6,431.6
Acquired IPR&D and development milestones	240.1	(45)%	$ 240.1	(45)%	437.7	437.7	908.5	(6)%	$ 908.5	(6)%	970.1	970.1
Asset impairment, restructuring, and other special charges	38.1	(64)%	(38.1)	$ - 0	NM	104.5	(104.5)	- 0	244.6	(23)%	(244.6)	$ - 0	NM	316.1	(316.1)	- 0
Operating income	1,836.4	(4)%	162.2	$ 1,998.6	(7)%	1,917.2	241.9	2,159.1	7,127.3	12 %	818.7	$ 7,946.0	5 %	6,357.1	1,224.9	7,582.0
Interest, net	(58.5)	$ (58.5)	(74.0)	(74.0)	(268.8)	$ (268.8)	(314.4)	(314.4)
Other income	318.5	(216.5)	$ 102.0	(3.3)	70.6	67.3	(52.1)	385.9	$ 333.8	112.8	227.2	340.0
Other - net, income (expense)	260.0	NM	(216.5)	$ 43.5	NM	(77.3)	70.6	(6.7)	(320.9)	59 %	385.9	$ 65.0	NM	(201.6)	227.2	25.6
Income before income taxes	2,096.4	14 %	(54.3)	$ 2,042.1	(5)%	1,839.9	312.5	2,152.4	6,806.4	11 %	1,204.6	$ 8,011.0	5 %	6,155.5	1,452.1	7,607.6
Income tax expense (benefit)	158.7	39 %	(9.7)	$ 149.0	(18)%	113.8	68.1	181.9	561.6	(2)%	263.0	$ 824.6	(6)%	573.8	300.1	873.9
Effective tax rate	7.6%	1.4	pp	7.3%	(1.2)	pp	6.2%	8.5%	8.3%	(1.0)	pp	10.3%	(1.2)	pp	9.3%	11.5%
Net income	$ 1,937.7	12 %	(44.6)	$ 1,893.1	(4)%	$ 1,726.1	244.4	$ 1,970.5	$ 6,244.8	12 %	941.6	$ 7,186.4	7 %	$ 5,581.7	1,152.0	$ 6,733.7
Earnings per share	$ 2.14	13 %	(0.05)	$ 2.09	(4)%	$ 1.90	0.27	$ 2.17	$ 6.90	13 %	1.04	$ 7.94	7 %	$ 6.12	1.27	$ 7.39
Diluted shares outstanding (thousands)	904,732	(1)%	904,732	(1)%	909,555	909,555	904,619	(1)%	904,619	(1)%	911,681	911,681
* The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and/or of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.
† For further detail of these adjustments, refer to our Earnings Release.
Note: Numbers may not add due to rounding.
Page 1 of 5 pages of financial data

2022 Revenue

LLY
Eli Lilly and Company
Product Revenue Report
2022
Investor Relations
Joe Fletcher [phone]
Michael Sprengnether [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
2022 Revenue
($ millions)	Q1	Q1	Q1	Q2	Q2	Q2	Q3	Q3	Q3	Q4	Q4	Q4	2022	2022	2022
US	Intl	Total	US	Intl	Total	US	Intl	Total	US	Intl	Total	US	Intl	Total
Baqsimi	22.5	6.7	29.2	21.8	7.2	29.0	35.2	7.8	43.0	30.8	7.2	38.1	110.4	28.9	139.3
Basaglar	119.3	72.2	191.5	95.8	78.4	174.2	124.8	68.1	193.0	130.8	70.9	201.7	470.7	289.7	760.4
Glucagon	5.9	1.1	6.9	6.8	1.0	7.7	9.4	0.9	10.3	6.6	0.9	7.5	28.7	3.8	32.5
Humalog(1)	368.9	249.3	618.2	238.8	208.3	447.1	248.1	198.8	447.0	336.0	212.3	548.3	1,191.9	868.7	2,060.6
Humulin	190.4	82.8	273.2	202.3	71.7	274.0	169.5	68.7	238.2	167.9	66.0	234.0	730.2	289.2	1,019.4
Jardiance(2)	229.8	189.7	419.4	250.7	210.3	461.0	350.9	222.4	573.3	363.1	249.2	612.3	1,194.5	871.5	2,066.0
Mounjaro	-	-	-	12.6	3.4	16.0	97.3	90.0	187.3	256.7	22.5	279.2	366.6	115.9	482.5
Trajenta(3)	19.6	72.4	92.0	23.7	73.4	97.1	28.5	75.3	103.8	17.8	73.0	90.8	89.5	294.2	383.7
Trulicity	1,313.9	427.4	1,741.3	1,430.1	481.7	1,911.9	1,418.3	432.0	1,850.4	1,526.4	409.8	1,936.2	5,688.8	1,750.9	7,439.7
Other Diabetes*	6.3	10.0	16.3	9.5	10.6	20.1	6.5	10.0	16.5	17.6	10.3	27.9	39.9	40.9	80.8
Diabetes	2,276.6	1,111.6	3,388.2	2,292.2	1,146.0	3,438.2	2,488.6	1,174.0	3,662.6	2,853.8	1,122.1	3,975.9	9,911.1	4,553.7	14,464.8
Olumiant	71.3	184.3	255.6	10.4	175.8	186.2	22.9	160.0	182.9	43.5	162.3	205.8	148.2	682.3	830.5
Taltz	307.2	180.8	488.1	411.6	194.7	606.2	493.8	186.1	679.9	512.0	195.8	707.8	1,724.6	757.4	2,482.0
Other Immunology*	-	4.5	4.5	-	4.0	4.0	-	3.6	3.6	20.0	-	20.0	20.0	12.1	32.1
Immunology	378.5	369.6	748.1	422.0	374.5	796.5	516.7	349.7	866.4	575.5	358.1	933.6	1,892.8	1,451.8	3,344.6
Cymbalta	9.1	71.9	81.1	8.1	67.4	75.5	7.8	54.9	62.7	8.7	55.4	64.0	33.7	249.6	283.3
Emgality	108.3	41.0	149.3	108.6	48.9	157.5	114.0	54.6	168.5	132.0	43.7	175.6	462.8	188.1	650.9
Reyvow	5.8	0.5	6.3	6.8	3.2	10.0	4.6	3.5	8.1	6.9	2.6	9.5	24.0	9.9	33.9
Strattera	2.8	30.7	33.5	(1.7)	30.6	28.9	(2.6)	25.0	22.4	2.4	29.0	31.4	0.9	115.3	116.2
Zyprexa	9.6	83.5	93.1	8.7	78.6	87.3	8.0	73.4	81.4	4.2	71.0	75.2	30.4	306.5	336.9
Other Neuroscience*	17.8	16.7	34.5	14.4	16.4	30.8	14.0	16.0	30.1	14.3	15.2	29.6	60.5	64.4	124.9
Neuroscience	153.4	244.4	397.7	144.8	245.2	389.9	145.8	227.4	373.2	168.5	216.8	385.3	612.4	933.8	1,546.2
Alimta	254.3	89.7	343.9	171.7	56.1	227.7	64.6	54.8	119.4	53.2	183.4	236.6	543.7	384.0	927.7
Cyramza	79.2	151.1	230.3	92.6	138.6	231.3	87.5	144.6	232.1	92.1	185.7	277.8	351.4	620.0	971.4
Elunate	-	27.6	27.6	-	21.6	21.6	-	23.7	23.7	-	18.0	18.0	-	91.0	91.0
Erbitux	109.7	13.0	122.7	125.1	15.7	140.8	126.3	18.7	144.9	139.1	19.1	158.2	500.1	66.4	566.5
Retevmo	32.9	8.8	41.8	38.3	6.7	45.0	32.2	8.4	40.5	39.1	25.5	64.6	142.5	49.4	191.9
Tyvyt	-	85.5	85.5	-	73.6	73.6	-	76.8	76.8	-	57.5	57.5	-	293.3	293.3
Verzenio	301.5	167.9	469.4	384.3	204.2	588.5	414.8	202.9	617.7	552.7	255.3	808.0	1,653.2	830.3	2,483.5
Other Oncology*	6.3	25.6	31.8	7.0	33.3	40.3	7.5	30.7	38.2	6.5	24.0	30.4	27.2	113.6	140.8
Oncology	783.7	569.2	1,353.0	819.0	549.8	1,368.7	732.7	560.6	1,293.3	882.6	768.5	1,651.1	3,218.1	2,448.1	5,666.1
COVID-19 Antibodies	1,455.2	14.7	1,469.8	129.1	-	129.1	386.6	-	386.6	38.0	-	38.0	2,008.9	14.7	2,023.5
Cialis	6.9	210.8	217.7	10.8	136.2	147.0	8.1	107.7	115.7	9.4	97.4	106.8	35.2	552.1	587.3
Forteo	70.2	67.3	137.4	78.5	60.0	138.5	112.7	64.4	177.1	105.9	54.1	160.0	367.3	245.8	613.1
Humatrope	14.4	27.3	41.7	19.5	26.2	45.6	13.5	21.2	34.7	8.3	11.2	19.4	55.6	85.9	141.5
Other*	35.8	20.5	56.2	19.0	15.6	34.6	17.3	14.4	31.7	16.6	15.0	31.6	88.7	65.5	154.2
Other	1,582.4	340.6	1,923.0	256.9	237.9	494.7	538.3	207.8	746.0	178.2	177.7	355.9	2,555.7	964.0	3,519.6
TOTAL REVENUE	5,174.6	2,635.4	7,810.0	3,934.8	2,553.3	6,488.0	4,422.1	2,519.4	6,941.6	4,658.6	2,643.2	7,301.8	18,190.0	10,351.3	28,541.4
*Other - Diabetes includes Actos, Competact, Evista, HumaPen, and Lyumjev. Other - Immunology includes Lebrikizumab. Other - Neuro includes Amyvid, Prozac, Symbyax, and Yentreve. Other - Oncology includes Gemzar, Halpryza, Portrazza, and Vitrakvi. Other - Other includes Adcirca, Ceclor, Effient, Keflex, Livalo, Zalutia, and other license fee income.
(1) Humalog revenue includes Insulin Lispro
(2) Jardiance revenue includes Glyxambi and Synjardy
(3) Trajenta revenue includes Jentadueto
Note: Numbers may not add due to rounding.
Page 2 of 5 pages of financial data

2022 Revenue Growth

LLY
Eli Lilly and Company
Product Revenue Growth Report
2022
Investor Relations
Joe Fletcher [phone]
Michael Sprengnether [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
2022 Revenue Growth
Q1	Q1	Intl	Q1	Q1	Q2	Q2	Intl	Q2	Q2	Q3	Q3	Intl	Q3	Q3	Q4	Q4	Intl	Q4	Q4	2022	2022	Intl	2022	2022
US	Intl	Perform**	Total	Perform**	US	Intl	Perform**	Total	Perform**	US	Intl	Perform**	Total	Perform**	US	Intl	Perform**	Total	Perform**	US	Intl	Perform**	Total	Perform**
Baqsimi	9 %	78 %	90 %	20 %	22 %	(2)%	98 %	NM	12 %	14 %	0	28 %	82 %	NM	35 %	38 %	19 %	42 %	63 %	23 %	26 %	14 %	72 %	92 %	23 %	26 %
Basaglar	(32)%	1 %	8 %	(22)%	(20)%	(28)%	1 %	9 %	(17)%	(15)%	9 %	(13)%	(2)%	- %	4 %	(21)%	(8)%	4 %	(17)%	(13)%	(20)%	(5)%	5 %	(15)%	(12)%
Glucagon	(71)%	(22)%	(22)%	(68)%	(68)%	(13)%	(36)%	(34)%	(17)%	(17)%	11 %	(54)%	(53)%	(1)%	(1)%	(5)%	(54)%	(51)%	(15)%	(15)%	(34)%	(44)%	(42)%	(36)%	(35)%
Humalog(1)	11 %	(12)%	(8)%	- %	2 %	(27)%	(25)%	(20)%	(26)%	(24)%	(29)%	(29)%	(21)%	(29)%	(25)%	8 %	(27)%	(19)%	(9)%	(5)%	(10)%	(23)%	(17)%	(16)%	(13)%
Humulin	(13)%	(19)%	(16)%	(15)%	(14)%	(8)%	(24)%	(18)%	(13)%	(11)%	(12)%	(26)%	(19)%	(17)%	(14)%	(16)%	(34)%	(25)%	(22)%	(19)%	(12)%	(26)%	(20)%	(17)%	(15)%
Jardiance(2)	52 %	18 %	25 %	34 %	38 %	29 %	30 %	40 %	29 %	34 %	59 %	31 %	48 %	47 %	54 %	51 %	30 %	48 %	42 %	50 %	48 %	28 %	41 %	39 %	45 %
Mounjaro	- %	- %	- %	- %	- %	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Trajenta(3)	(7)%	(2)%	1 %	(3)%	(1)%	41 %	1 %	4 %	9 %	11 %	21 %	4 %	9 %	8 %	12 %	(15)%	2 %	7 %	(2)%	2 %	9 %	1 %	5 %	3 %	6 %
Trulicity	18 %	27 %	35 %	20 %	22 %	25 %	24 %	34 %	25 %	27 %	18 %	8 %	23 %	16 %	19 %	5 %	(6)%	8 %	3 %	6 %	16 %	12 %	24 %	15 %	18 %
Other Diabetes*	36 %	14 %	42 %	40 %	46 %	36 %	14 %	25 %	24 %	30 %	62 %	(3)%	12 %	15 %	26 %	12 %	(11)%	4 %	2 %	8 %	29 %	6 %	19 %	16 %	23 %
Diabetes	10 %	7 %	13 %	9 %	11 %	10 %	5 %	13 %	9 %	11 %	16 %	6 %	18 %	13 %	17 %	17 %	(5)%	7 %	10 %	14 %	14 %	3 %	12 %	10 %	13 %
Olumiant	NM	9 %	17 %	32 %	39 %	(41)%	(8)%	2 %	(11)%	(2)%	(88)%	(25)%	(13)%	(55)%	(49)%	(50)%	(26)%	(12)%	(33)%	(23)%	(54)%	(14)%	(3)%	(26)%	(18)%
Taltz	23 %	18 %	27 %	21 %	24 %	3 %	15 %	25 %	7 %	9 %	17 %	9 %	23 %	15 %	19 %	9 %	11 %	26 %	9 %	14 %	12 %	13 %	25 %	12 %	16 %
Other Immunology*	- %	(29)%	(29)%	(29)%	(29)%	- %	25 %	25 %	25 %	25 %	- %	(27)%	(27)%	(27)%	(27)%	- %	NM	NM	NM	NM	- %	(32)%	(32)%	82 %	82 %
Immunology	38 %	12 %	21 %	24 %	29 %	1 %	3 %	13 %	2 %	6 %	(16)%	(10)%	3 %	(14)%	(9)%	3 %	(10)%	4 %	(2)%	4 %	1 %	(2)%	10 %	- %	5 %
Cymbalta	(17)%	(57)%	(54)%	(54)%	(51)%	(35)%	(59)%	(55)%	(57)%	(54)%	12 %	(56)%	(50)%	(53)%	(47)%	3 %	(38)%	(28)%	(34)%	(25)%	(13)%	(54)%	(49)%	(51)%	(47)%
Emgality	7 %	NM	NM	25 %	26 %	(3)%	11 %	21 %	1 %	4 %	14 %	36 %	58 %	20 %	27 %	9 %	8 %	20 %	9 %	12 %	7 %	32 %	46 %	13 %	16 %
Reyvow	NM	NM	NM	NM	NM	(28)%	NM	NM	7 %	7 %	(15)%	NM	NM	54 %	54 %	8 %	NM	NM	39 %	39 %	1 %	NM	NM	41 %	41 %
Strattera	(53)%	(6)%	(1)%	(13)%	(9)%	NM	(7)%	- %	(29)%	(23)%	NM	(23)%	(15)%	(36)%	(28)%	NM	(17)%	(6)%	(13)%	(2)%	(95)%	(13)%	(5)%	(23)%	(16)%
Zyprexa	39 %	(6)%	- %	(3)%	3 %	3 %	(10)%	(2)%	(8)%	(1)%	(39)%	(17)%	(6)%	(20)%	(11)%	(63)%	(44)%	(36)%	(45)%	(38)%	(23)%	(22)%	(13)%	(22)%	(14)%
Other Neuroscience*	29 %	(10)%	(1)%	7 %	12 %	(14)%	(11)%	(8)%	(12)%	(11)%	(16)%	(17)%	(12)%	(16)%	(14)%	7 %	(16)%	(11)%	(6)%	(3)%	- %	(13)%	(8)%	(7)%	(4)%
Neuroscience	8 %	(25)%	(20)%	(15)%	(11)%	(13)%	(29)%	(23)%	(24)%	(20)%	1 %	(26)%	(16)%	(17)%	(10)%	4 %	(30)%	(20)%	(18)%	(12)%	- %	(27)%	(20)%	(19)%	(14)%
Alimta	(3)%	(70)%	(68)%	(38)%	(38)%	(51)%	(78)%	(77)%	(63)%	(62)%	(78)%	(66)%	(62)%	(74)%	(73)%	(83)%	63 %	70 %	(46)%	(44)%	(56)%	(54)%	(51)%	(55)%	(54)%
Cyramza	(1)%	(6)%	4 %	(4)%	2 %	(9)%	(17)%	(7)%	(14)%	(7)%	3 %	(14)%	(1)%	(8)%	- %	- %	4 %	18 %	3 %	12 %	(2)%	(8)%	4 %	(6)%	2 %
Elunate	- %	39 %	36 %	39 %	36 %	- %	12 %	13 %	12 %	13 %	- %	30 %	36 %	30 %	36 %	- %	52 %	70 %	52 %	70 %	- %	31 %	35 %	31 %	35 %
Erbitux	2 %	(10)%	(4)%	- %	1 %	(8)%	40 %	70 %	(4)%	(2)%	11 %	(8)%	19 %	8 %	12 %	12 %	(7)%	26 %	9 %	14 %	4 %	- %	25 %	3 %	6 %
Retevmo	NM	NM	NM	NM	NM	70 %	NM	NM	75 %	76 %	10 %	89 %	NM	21 %	23 %	24 %	NM	NM	67 %	72 %	43 %	NM	NM	67 %	70 %
Tyvyt	- %	(22)%	(24)%	(22)%	(24)%	- %	(30)%	(29)%	(30)%	(29)%	- %	(39)%	(36)%	(39)%	(36)%	- %	(26)%	(18)%	(26)%	(18)%	- %	(30)%	(28)%	(30)%	(28)%
Verzenio	74 %	74 %	86 %	74 %	79 %	83 %	55 %	67 %	72 %	77 %	NM	49 %	71 %	84 %	93 %	NM	69 %	94 %	100 %	NM	98 %	61 %	80 %	84 %	91 %
Other Oncology	48 %	(17)%	(18)%	(9)%	(10)%	27 %	8 %	10 %	11 %	12 %	23 %	(27)%	(24)%	(21)%	(18)%	33 %	10 %	22 %	14 %	24 %	32 %	(10)%	(6)%	(4)%	(1)%
Oncology	22 %	(22)%	(18)%	(1)%	1 %	(1)%	(24)%	(18)%	(12)%	(9)%	- %	(17)%	(7)%	(8)%	(3)%	7 %	32 %	48 %	17 %	24 %	6 %	(10)%	(1)%	(1)%	3 %
COVID-19 Antibodies	124 %	(91)%	(91)%	81 %	81 %	55 %	(100)%	(100)%	(13)%	(13)%	79 %	(100)%	(100)%	78 %	78 %	(96)%	(100)%	(100)%	(96)%	(96)%	2 %	(94)%	(94)%	(10)%	(10)%
Cialis	(20)%	78 %	86 %	72 %	78 %	NM	(52)%	(51)%	(48)%	(47)%	NM	(22)%	(19)%	(12)%	(8)%	(31)%	(41)%	(38)%	(41)%	(38)%	NM	(22)%	(19)%	(18)%	(15)%
Forteo	(28)%	(33)%	(29)%	(31)%	(28)%	(36)%	(37)%	(32)%	(37)%	(34)%	3 %	(29)%	(21)%	(12)%	(8)%	(5)%	(25)%	(15)%	(13)%	(9)%	(17)%	(32)%	(25)%	(24)%	(20)%
Humatrope	(55)%	(16)%	(9)%	(36)%	(32)%	NM	(20)%	(11)%	NM	NM	(30)%	(31)%	(21)%	(31)%	(24)%	(63)%	(61)%	(54)%	(62)%	(58)%	(13)%	(31)%	(23)%	(25)%	(19)%
Other*	10 %	(31)%	(26)%	(9)%	(7)%	(11)%	(55)%	(50)%	(38)%	(35)%	(7)%	(68)%	(63)%	(50)%	(47)%	(6)%	(70)%	(65)%	(53)%	(50)%	(2)%	(59)%	(54)%	(38)%	(35)%
Other	93 %	(23)%	(19)%	52 %	54 %	21 %	(54)%	(51)%	(32)%	(30)%	51 %	(32)%	(26)%	13 %	15 %	(85)%	(49)%	(45)%	(77)%	(76)%	(1)%	(40)%	(36)%	(16)%	(15)%
TOTAL REVENUE	31 %	(8)%	(3)%	15 %	17 %	6 %	(16)%	(9)%	(4)%	(1)%	11 %	(9)%	1 %	2 %	7 %	(10)%	(6)%	5 %	(9)%	(5)%	8 %	(10)%	(2)%	1 %	4 %
*Other - Diabetes includes Actos, Competact, HumaPen, and Lyumjev. Other - Immunology includes Lebrikizumab. Other - Neuro includes Amyvid, Prozac, Symbyax, and Yentreve. Other - Oncology includes Gemzar, Halpryza, Portrazza, and Vitrakvi. Other - Other includes Adcirca, Effient, Evista, Keflex, Livalo, Zalutia, and other license fee income.
**Performance excludes the impact of foreign exchange rates
(1) Humalog revenue includes Insulin Lispro
(2) Jardiance revenue includes Glyxambi and Synjardy
(3) Trajenta revenue includes Jentadueto
Note: Numbers may not add due to rounding.
Page 3 of 5 pages of financial data

PRV

LLY
Eli Lilly and Company
Effect of Price, Rate, Volume on Revenue
Investor Relations
Joe Fletcher [phone]
Michael Sprengnether [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
As Reported ($ millions)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	2022 FY
$	Price	Rate	Volume	Total	$	Price	Rate	Volume	Total	$	Price	Rate	Volume	Total	$	Price	Rate	Volume	Total	$	Price	Rate	Volume	Total
Region
U.S.	$ 5,174.6	(1)%	- %	32 %	31 %	$ 3,934.8	(8)%	- %	14 %	6 %	$ 4,422.1	(4)%	- %	15 %	11 %	$ 4,658.6	- %	- %	(10)%	(10)%	$ 18,190.0	(3)%	- %	11 %	8 %
Europe	1,067.3	(3)%	(6)%	(10)%	(19)%	1,101.1	(2)%	(10)%	2 %	(9)%	1,056.4	(3)%	(15)%	14 %	(4)%	1,074.5	(4)%	(14)%	12 %	(6)%	4,299.2	(3)%	(11)%	4 %	(10) %
Japan	410.2	(3)%	(7)%	(18)%	(28)%	454.4	(5)%	(10)%	(17)%	(32)%	487.7	(4)%	(16)%	3 %	(18)%	395.0	(4)%	(20)%	(3)%	(26)%	1,747.3	(4)%	(13)%	(9)%	(26)%
China	406.5	(36)%	2 %	46 %	12 %	352.1	(73)%	(1)%	41 %	(33)%	343.4	(67)%	(4)%	57 %	(14)%	350.8	(30)%	(8)%	32 %	(7)%	1,452.8	(54)%	(3)%	44 %	(13)%
ROW	751.5	(3)%	(6)%	32 %	23 %	645.7	(1)%	(2)%	4 %	1 %	632.0	(1)%	(3)%	(4)%	(8)%	822.9	(3)%	(4)%	14 %	8 %	2,852.0	(2)%	(3)%	11 %	6 %
Total Revenue	$ 7,810.0	(3)%	(2)%	20 %	15 %	$ 6,488.0	(11)%	(3)%	10 %	(4)%	$ 6,941.6	(7)%	(4)%	14 %	2 %	$ 7,301.8	(3)%	(4)%	(2)%	(9)%	$ 28,541.4	(6)%	(3)%	10 %	1 %
ROW - OUS excluding Europe, Japan, and China
Note: Numbers may not add due to rounding.
Page 4 of 5 pages of financial data

OID

LLY
Eli Lilly and Company
Other Income/(Deductions)
Investor Relations
Joe Fletcher [phone]
Michael Sprengnether [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
2022	2021
As Reported
$ Millions	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Q4	Total
- Interest expense	$ (84.9)	$ (81.2)	$ (81.5)	$ (84.0)	$ (331.6)	$ (87.8)	$ (86.9)	$ (83.6)	$ (81.4)	$ (339.8)
- Interest income	7.0	10.2	20.1	25.5	62.8	5.5	5.4	7.0	7.4	25.4
Interest - net	(77.9)	(71.0)	(61.4)	(58.5)	(268.8)	(82.3)	(81.5)	(76.6)	(74.0)	(314.4)
Other income, net
- FX gain (loss)	(12.0)	(19.7)	(30.8)	(18.4)	(80.9)	(10.6)	(10.8)	(10.9)	(5.4)	(37.8)
- Gain (loss) equity investments	(425.4)	(118.9)	(123.3)	256.9	(410.7)	301.5	215.7	(246.8)	(93.5)	176.9
- Gain (loss) debt extinguishment	-	-	-	-	-	-	-	(405.2)	-	(405.2)
- Miscellaneous income (expense)	71.3	(3.9)	12.1	(12.9)	66.6	39.1	(4.0)	31.0	23.0	89.2
- Retirement Benefit	93.3	94.3	92.4	92.9	372.9	73.4	71.1	72.6	72.6	289.7
Other income (expense)	(272.8)	(48.2)	(49.6)	318.5	(52.1)	403.4	272.0	(559.3)	(3.3)	112.8
Other - net, income (expense)	$ (350.7)	$ (119.2)	$ (111.0)	$ 260.0	$ (320.9)	$ 321.1	$ 190.5	$ (635.9)	$ (77.3)	$ (201.6)
2022	2021
Non-GAAP*
$ Millions	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Q4	Total
- Interest expense	$ (84.9)	$ (81.2)	$ (81.5)	$ (84.0)	$ (331.6)	$ (87.8)	$ (86.9)	$ (83.6)	$ (81.4)	$ (339.8)
- Interest income	7.0	10.2	20.1	25.5	62.8	5.5	5.4	7.0	7.4	25.4
Interest - net	(77.9)	(71.0)	(61.4)	(58.5)	(268.8)	(82.3)	(81.5)	(76.6)	(74.0)	(314.4)
Other income, net
- FX gain (loss)	(12.0)	(19.7)	(30.8)	(18.4)	(80.9)	(10.6)	(10.8)	(10.9)	(5.4)	(37.8)
- Miscellaneous income (expense)	34.3	(16.5)	(3.5)	27.5	41.8	54.1	26.2	7.6	0.1	88.1
- Retirement Benefit	93.3	94.3	92.4	92.9	372.9	73.4	71.1	72.6	72.6	289.7
Other income (expense)	115.6	58.1	58.1	102.0	333.8	116.9	86.5	69.3	67.3	340.0
Other - net, income (expense)	$ 37.7	$ (12.9)	$ (3.3)	$ 43.5	$ 65.0	$ 34.6	$ 5.0	$ (7.3)	$ (6.7)	$ 25.6
*The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and/or of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.
Note: Numbers may not add due to rounding.
Page 5 of 5 pages of financial data